AnaptysBio, Inc., established in Delaware in November 2005. The company is a clinical-stage biotechnology company focused on delivering innovative immunological therapies. The Company is developing immune cell regulating antibodies, including two wholly-owned checkpoint agonists in clinical stage development for autoimmune and inflammatory diseases: rosnilimab, a Phase 2 trial of the Company's PD-1 agonist for the treatment of moderate to severe rheumatoid arthritis (" RA ") and a Phase 2 trial for the treatment of moderate to severe ulcerative colitis (" UC "); ANB032, the Company's BTLA agonist, Phase 2 trial for the treatment of moderate to severe atopic dermatitis (" AD "). 

Expected P&L on Expiry

Key Stats

Pricing Model

About ANAB20260220C45